|Dr. Wei-Wu He||Chairman & CEO||1.44M||N/A||1965|
|Dr. Wei Zhang Ph.D.||Pres||345.1k||N/A||1959|
|Mr. George Chi C.F.A., CPA||Chief Financial Officer||300.06k||N/A||1969|
|Ms. Cynthia Wong Hu||COO, Gen. Counsel & Sec.||N/A||N/A||1970|
|Ms. Sara B. Capitelli||VP of Fin. & Principal Accounting Officer||N/A||N/A||1966|
CASI Pharmaceuticals, Inc., a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprises ZEVALIN, an ibritumomab tiuxetan injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-Hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-Hodgkin's lymphoma; and MARQIBO, a microtubule inhibitor to treat adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. In addition, the company engages in the development of a portfolio of 26 FDA-approved abbreviated new drug applications (ANDAs), including entecavir and tenofovir disoproxil fumarate indicated for hepatitis B virus; and 4 pipeline ANDAs that are pending FDA approval. Further, it is involved in developing ENMD-2076, an Aurora A/angiogenic kinase inhibitor that has completed Phase II studies for solid tumors, as well as various proprietary early-stage immune-oncological potential candidates in preclinical development. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.
CASI Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 8. The pillar scores are Audit: 3; Board: 9; Shareholder Rights: 4; Compensation: 9.